Carette S, Leclaire R, Marcoux S, Morin F, Blaise G A, St-Pierre A, Truchon R, Parent F, Levésque J, Bergeron V, Montminy P, Blanchette C
Department of Medicine, Laval University, Quebec City, Canada.
N Engl J Med. 1997 Jun 5;336(23):1634-40. doi: 10.1056/NEJM199706053362303.
Although epidural corticosteroid injections are commonly used for sciatica, their efficacy has not been established.
In a randomized, double-blind trial, we administered up to three epidural injections of methylprednisolone acetate (80 mg in 8 ml of isotonic saline) or isotonic saline (1 ml) to 158 patients with sciatica due to a herniated nucleus pulposus. All patients had Oswestry disability scores higher than 20 (on a scale of 1 to 100, with scores of 20 or less indicating minimal disability, and higher scores greater disability).
At three weeks, the Oswestry score had improved by a mean of -8.0 in the methylprednisolone group and -5.5 in the placebo group (95 percent confidence interval for the difference, -7.1 to 2.2). Differences in improvements between the groups were not significant, except for improvements in the finger-to-floor distance (P=0.006) and sensory deficits (P=0.03), which were greater in the methylprednisolone group. After six weeks, the only significant difference was the improvement in leg pain, which was greater in the methylprednisolone group (P=0.03). After three months, there were no significant differences between the groups. The Oswestry score had improved by a mean of -17.3 in the methylprednisolone group and -15.4 in the placebo group (95 percent confidence interval for the difference, -9.3 to 5.4). At 12 months, the cumulative probability of back surgery was 25.8 percent in the methylprednisolone group and 24.8 percent in the placebo group (P=0.90).
Although epidural injections of methylprednisolone may afford short-term improvement in leg pain and sensory deficits in patients with sciatica due to a herniated nucleus pulposus, this treatment offers no significant functional benefit, nor does it reduce the need for surgery.
尽管硬膜外注射皮质类固醇常用于治疗坐骨神经痛,但其疗效尚未得到证实。
在一项随机双盲试验中,我们对158例因腰椎间盘突出症导致坐骨神经痛的患者,给予最多三次硬膜外注射醋酸甲泼尼龙(80毫克溶于8毫升等渗盐水中)或等渗盐水(1毫升)。所有患者的奥斯维斯特里功能障碍评分均高于20分(评分范围为1至100分,20分及以下表示功能障碍极小,分数越高功能障碍越严重)。
在三周时,甲泼尼龙组的奥斯维斯特里评分平均改善了-8.0分,安慰剂组改善了-5.5分(两组差异的95%置信区间为-7.1至2.2)。除了指尖到地面距离(P=0.006)和感觉障碍(P=0.03)的改善在甲泼尼龙组更大外,两组之间的改善差异不显著。六周后,唯一显著的差异是腿部疼痛的改善,甲泼尼龙组更大(P=0.0得3)。三个月后,两组之间无显著差异。甲泼尼龙组的奥斯维斯特里评分平均改善了-17.3分,安慰剂组改善了-15.4分(两组差异的95%置信区间为-9.3至5.4)。在12个月时,甲泼尼龙组进行背部手术的累积概率为25.8%,安慰剂组为24.8%(P=0.90)。
尽管硬膜外注射甲泼尼龙可能使因腰椎间盘突出症导致坐骨神经痛的患者的腿部疼痛和感觉障碍得到短期改善,但这种治疗没有显著的功能益处,也不能减少手术需求。